Phase 3 Obesity Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People of any sex, race, or ethnic background who fall into one of three groups: adults aged 18–30 with a healthy weight (BMI 18.5–24.9), adults aged 18–30 with obesity (BMI 30–39.9), or adults aged 65 and older with obesity (BMI 30–39.9)
• People who live independently in the community (not in a care facility)
• People who do very little structured exercise — no more than 1.5 hours per week
• People who do not have diabetes, based on blood sugar test results falling within specific normal ranges
• Female participants who are not pregnant or breastfeeding, and who either cannot become pregnant (due to procedures such as hysterectomy, removal of both fallopian tubes, or removal of both ovaries) or who use a highly effective form of contraception during the study and for at least 30 days after the last dose of the study treatment
• People whose heart tracing (ECG) results fall within specific normal ranges after resting for 10 minutes, or whose results are reviewed and considered not medically significant by the study investigator

Who may not be able to join:

• People who have been diagnosed with diabetes, or whose blood sugar or HbA1c levels are above specific thresholds, or who take diabetes medications
• People who do more than 1.5 hours of structured exercise per week
• People whose weight has changed by more than 3% in the past 3 months
• People with neurological, musculoskeletal, or other conditions that could limit their ability to complete physical assessments or training in the study
• People with active autoimmune or inflammatory conditions, such as rheumatoid arthritis, multiple sclerosis, lupus, or inflammatory bowel disease
• People with certain abnormal blood test results, including reduced kidney function, reduced liver function, abnormal bilirubin levels, abnormal thyroid hormone levels, low haemoglobin, low platelet count, or abnormal blood clotting times (confirm specific thresholds with trial site)
• People with active digestive (gastrointestinal) disease, a blood clotting disorder, or a gastrointestinal bleed within the past 6 months
• People with significant heart disease
• People with peripheral vascular disease (poor circulation causing leg pain when walking)
• People with a particular type of abnormal heart rhythm measurement (QTc prolongation above 45 msec)
• People taking certain heart rhythm medications, blood-thinning medications, or anti-platelet medications
• People taking quinolone antibiotics or other medications known to affect heart rhythm (confirm specific medications with trial site)
• People with chronic lung disease (COPD), severe asthma, or exercise-induced asthma
• People who have recently had a blood clot in the lungs or major blood vessels
• People with uncontrolled high blood pressure above specific levels
• People who currently smoke, drink alcohol above certain weekly limits (more than 7 drinks per week for women or 14 drinks per week for men), or use recreational drugs other than marijuana
• People who are pregnant or breastfeeding
• Women who have recently gone through menopause and started systemic hormone replacement therapy within the past 6 months
• People who have previously had bariatric (weight loss) surgery
• People with a history of stroke that caused lasting movement difficulties
• People who have been treated for cancer (other than a type of minor skin cancer called basal cell carcinoma) within the past 3 years
• People with a current acute or chronic infection
• People who have taken certain medications that may affect metabolism — including weight loss medications, systemic steroids, or immune-suppressing drugs — within the past 6 months
• People who have taken certain supplements or medications considered potentially "senolytic" (such as fisetin, quercetin, luteolin, dasatinib, piperlongumine, or navitoclax) within the past 6 months
• People with a known allergy to dasatinib, quercetin, or lidocaine
• People who are currently enrolled in another interventional clinical trial

Important: Always verify eligibility with the trial site directly before applying.